Search

Your search keyword '"Fang, Zhaoyuan"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Fang, Zhaoyuan" Remove constraint Author: "Fang, Zhaoyuan" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
41 results on '"Fang, Zhaoyuan"'

Search Results

1. Analogy-Forming Transformers for Few-Shot 3D Parsing

2. TIDEE: Tidying Up Novel Rooms using Visuo-Semantic Commonsense Priors

3. Simple-BEV: What Really Matters for Multi-Sensor BEV Perception?

4. Particle Video Revisited: Tracking Through Occlusions Using Point Trajectories

6. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

7. Review of Iris Presentation Attack Detection Competitions

8. Review of Iris Presentation Attack Detection Competitions

10. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer.

16. Figure S2 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

17. Data from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

18. Table S1 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

19. Supplementary Figure Legend from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

20. Table S1 from Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

21. Supplementary Table 1 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

22. Supplementary Figure 2 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

23. Supplementary Figure 4 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

24. Supplementary Table 2 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

25. Supplementary Figure 1 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

26. Data from Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

27. Supplementary Table 3 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

28. Supplementary Data from Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

29. Supplementary Figure 3 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

30. Data from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

31. Supplementary Figure Legends 1-12 from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

32. Supplementary Figures 1-12 from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

33. Supplementary Methods from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

34. Supplementary Table 1 from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

35. Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment

37. Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer

38. Integrative analysis of multi‐omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer

39. TransRef enables accurate transcriptome assembly by redefining accurate neo-splicing graphs.

40. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation

41. HMPA: a pioneering framework for the noncanonical peptidome from discovery to functional insights.

Catalog

Books, media, physical & digital resources